Abstract
Background: Obese patients have myocardial structural and functional alterations related to insulin resistance. Hypothesis: The purpose of the study was to analyze the effects of rosiglitazone, an insulin sensitizer agent, on cardiac morphometry and functioning. Methods: In 2 groups of sex- and age-matched, nondiabetic, obese patients (5 men and 7 women, age 19-51 y; group A: body mass index [BMI] 40.6±3.4 kg/m2; group B: BMI 42.6±2.7 kg/m2), we evaluated the basal insulin sensitivity index (HOMA[IS]), body composition by bioelectrical impedance analysis and 24-h blood pressure monitoring. Furthermore, all patients underwent conventional 2-Dimensional and color Doppler echocardiography, and pulsed-wave tissue Doppler imaging (TDI). After the baseline evaluation, all patients were put on a hypocaloric diet (70% basal metabolic rate) plus placebo if they were in group A, or plus rosiglitazone (4 mg twice daily; Avandia [GlaxoSmithKline plc., Brentford, Middlesex, United Kingdom]) if they were in group B, for 6 mo. Results: Significant decreases in body weight, total fat mass, BMI, and systolic blood pressure were registered in both groups. Rosiglitazone administration appeared more efficient in improving HOMA(IS) (mean difference: 0.30±0.19 versus 0.11±0.21, p
| Original language | English |
|---|---|
| Pages (from-to) | 602-606 |
| Number of pages | 5 |
| Journal | Clinical Cardiology |
| Volume | 31 |
| Issue number | 12 |
| DOIs | |
| Publication status | Published - Dec 2008 |
Fingerprint
Keywords
- Left ventricular function
- Obesity
- Rosiglitazone
- Tissue doppler imaging
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
Evaluation of rosiglitazone administration on cardiovascular function in severe obesity. / Brunani, Amelia; Liuzzi, Antonio; Titon, AnnaMaria; Graci, Salvatore; Castagna, Giovanna; Viberti, Gian Carlo; Gondoni, Luca A.
In: Clinical Cardiology, Vol. 31, No. 12, 12.2008, p. 602-606.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Evaluation of rosiglitazone administration on cardiovascular function in severe obesity
AU - Brunani, Amelia
AU - Liuzzi, Antonio
AU - Titon, AnnaMaria
AU - Graci, Salvatore
AU - Castagna, Giovanna
AU - Viberti, Gian Carlo
AU - Gondoni, Luca A.
PY - 2008/12
Y1 - 2008/12
N2 - Background: Obese patients have myocardial structural and functional alterations related to insulin resistance. Hypothesis: The purpose of the study was to analyze the effects of rosiglitazone, an insulin sensitizer agent, on cardiac morphometry and functioning. Methods: In 2 groups of sex- and age-matched, nondiabetic, obese patients (5 men and 7 women, age 19-51 y; group A: body mass index [BMI] 40.6±3.4 kg/m2; group B: BMI 42.6±2.7 kg/m2), we evaluated the basal insulin sensitivity index (HOMA[IS]), body composition by bioelectrical impedance analysis and 24-h blood pressure monitoring. Furthermore, all patients underwent conventional 2-Dimensional and color Doppler echocardiography, and pulsed-wave tissue Doppler imaging (TDI). After the baseline evaluation, all patients were put on a hypocaloric diet (70% basal metabolic rate) plus placebo if they were in group A, or plus rosiglitazone (4 mg twice daily; Avandia [GlaxoSmithKline plc., Brentford, Middlesex, United Kingdom]) if they were in group B, for 6 mo. Results: Significant decreases in body weight, total fat mass, BMI, and systolic blood pressure were registered in both groups. Rosiglitazone administration appeared more efficient in improving HOMA(IS) (mean difference: 0.30±0.19 versus 0.11±0.21, p
AB - Background: Obese patients have myocardial structural and functional alterations related to insulin resistance. Hypothesis: The purpose of the study was to analyze the effects of rosiglitazone, an insulin sensitizer agent, on cardiac morphometry and functioning. Methods: In 2 groups of sex- and age-matched, nondiabetic, obese patients (5 men and 7 women, age 19-51 y; group A: body mass index [BMI] 40.6±3.4 kg/m2; group B: BMI 42.6±2.7 kg/m2), we evaluated the basal insulin sensitivity index (HOMA[IS]), body composition by bioelectrical impedance analysis and 24-h blood pressure monitoring. Furthermore, all patients underwent conventional 2-Dimensional and color Doppler echocardiography, and pulsed-wave tissue Doppler imaging (TDI). After the baseline evaluation, all patients were put on a hypocaloric diet (70% basal metabolic rate) plus placebo if they were in group A, or plus rosiglitazone (4 mg twice daily; Avandia [GlaxoSmithKline plc., Brentford, Middlesex, United Kingdom]) if they were in group B, for 6 mo. Results: Significant decreases in body weight, total fat mass, BMI, and systolic blood pressure were registered in both groups. Rosiglitazone administration appeared more efficient in improving HOMA(IS) (mean difference: 0.30±0.19 versus 0.11±0.21, p
KW - Left ventricular function
KW - Obesity
KW - Rosiglitazone
KW - Tissue doppler imaging
UR - http://www.scopus.com/inward/record.url?scp=58149098313&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=58149098313&partnerID=8YFLogxK
U2 - 10.1002/clc.20339
DO - 10.1002/clc.20339
M3 - Article
VL - 31
SP - 602
EP - 606
JO - Clinical Cardiology
JF - Clinical Cardiology
SN - 0160-9289
IS - 12
ER -